Gynecologic Cancer Steering Committee

The NCI Gynecologic Cancer Steering Committee (GCSC) was transitioned into a NCI Disease Specific Steering Committee from the Gynecologic Cancer Intergroup in May 2006. The GCSC is currently composed of the Steering Committee and three specific disease-site task forces. Members of the GCSC include Cooperative Group gynecologic disease committee chairs, Specialized Programs of Research Excellence (SPOREs), Cancer Center, and R01/P01 investigators along with community oncologists, biostatistician(s), patient advocates, and NCI staff.

Mission Statement

The GCSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in gynecologic cancer clinical research by addressing the design and prioritization of phase III trials and evaluating randomized phase II studies. As part of its mission, this GCSC is intent on fostering collaboration with international groups and institutions engaged in conducting trials in gynecologic cancers.

Roster of Gynecologic Cancer Steering Committee (GCSC) members
William J. Hoskins, M.D., Gillian M. Thomas, M.D. and Michael J. Birrer, M.D., Ph.D., Co-chairs

Task Forces

• Cervical Cancer: Marie Plante, M.D., Co-chair, and Anthony H. (Tim) Russell, M.D., Co-chair
• Ovarian Cancer: Benjamin E. Greer, M.D., Co-chair, and Ken Swenerton, M.D., Co-chair
• Uterine Cancer: Richard R. Barakat, M.D., Co-chair, and Richard J. Zaino, M.D., Co-chair

Clinical Trials Planning Meetings

• Cervical Cancer State of the Science Meeting (Sept. 27-28, 2007) (PDF, 18 kb)
• Endometrial Cancer State of the Science Meeting (Nov. 28-29, 2006) (PDF, 18 kb)

Active Protocols

• GOG-0240: Phase III Randomized Study of Paclitaxel in Combination With Cisplatin or Topotecan Hydrochloride With Versus Without Bevacizumab in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix
  Active Activation date: 4/6/09
• GOG-0249: Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma
  Activation date: 3/23/09
• GOG-0248: Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma
  Activation date: 9/29/08
• GOG-0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
  Activation date: 2/25/08
• GOG-0213: Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
  Activation date: 12/6/07

To search all active clinical trials, go to: http://www.cancer.gov/clinicaltrials/search

Publications

• Kitchner, H. C. and Trimble, E.L. Endometrial Cancer State of the Science Meeting . Int J Gynecol Cancer, 2009;19:134-140.
• Trimble, E. L. (for the Cervical SOTS writing Committee). Cervical Cancer State-of-the-Clinical-Science Meeting on Pretreatment Evaluation and Prognostic Factors, September 27-28, 2007: Proceedings and Recommendations. Gynecol Oncol, accepted for publication.

CCCT Contact: Raymond Petryshyn, Ph.D.